23. AGAH Annual Meeting 2014
Risk mitigation in early medicines development is the focus of the 2014 Annual Meeting in Munich. Whereas recent meetings mainly addressed aspects of early clinical utility assessment and exploratory development of modern therapies, there is need for an overall evaluation of risks and in consequence for the advancement of mitigation strategies.
A broad range of approaches is offered such as the impact of nonclinical findings, biopharmaceutics, personalised medicine approaches, updates on safety/tolerability from a clinical pharmacology perspective, as well as early investigation of lack of efficacy. Risk mitigation is increasingly important in early medicines development not only to allow early attrition but also to improve the chances of early drug development.
In Plenary Sessions and Parallel Workshops with much room for discussion the AGAH Annual Meeting 2014 will provide a floor for comprehensive exchange on these topics. As the conference is located in Munich the AGAH has taken the initiative to cooperate with BioM (Biotech Cluster Development GmbH, a nonprofit organisation) in preparing the conference and thereby involve speakers from Munich’s biotechnology sector.
Dr. Kerstin Breithaupt-Grögler
President AGAH e.V.
Prof. Dr. Hildegard Sourgens
President Elect AGAH e.V.
Dienstag, 18. Februar 2014, 15.00 Uhr bis ca. 18.00 Uhr
Kardinal Wendel Haus, Katholische Akademie in Bayern, Mandlstraße 23, D-80802 München, Phone: 0 89 / 38 10 2-0
Programm und weitere Informationen